1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
2. Noyes R,Woodman C, Garvey MJ, Cook BL. Generalized anxiety disorder vs. panic disorder: distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis. 1992;180:369-379.
3. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16:162-171.
4. Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse, and illness—course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety. 2003;17:173-179.
5.Batelaan N, Smit F, de Graaf R, et al. Economic costs of full-blown and subthreshold panic disorder. J Affect Disord. 2007;104:127-136.
6. Kessler RC, Chiu WT, Jin R, et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63:415-424.
7. Goodwin RD, Lieb R, Hoefler M, et al. Panic attack as a risk factor for severe psychopathology. Am J Psychiatry. 2004;161:2207-2214.
8. Kessler RC, Andrade LH, Bijl RV, et al. The effects of co-morbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys: International Consortium in Psychiatric Epidemiology. Psychol Med. 2002;32:1213-1225.
9. Labrecque J, Dugas MJ, Marchand A, Letarte A. Cognitive-behavioral therapy for comorbid generalized anxiety disorder and panic disorder with agoraphobia. Behav Modif. 2006;30:383-410.
10. Roemer L, Orsillo SM, Salters-Pedneault K. Efficacy of an acceptance-based behavior therapy for generalized anxiety disorder: evaluation in a randomized controlled trial. J Consult Clin Psychol. 2008;76: 1083-1089.
11. Tsao JC, Mystkowski JL, Zucker BG, Craske MG. Impact of cognitive-behavioral therapy for panic disorder on comorbidity: a controlled investigation. Behav Res Ther. 2005;43:959-970.
12. Provencher MD, Ladouceur R, Dugas MJ. Comorbidity in generalized anxiety disorder: prevalence and course after cognitive-behavior therapy [in French]. Can J Psychiatry. 2006;51:91-99.
13. Roemer L, Orsillo SM. Mindfulness- and Acceptance- Based Behavioral Therapies in Practice. New York: Guilford Press; 2008.
14. Roy-Byrne P, Wingerson D, Cowley D, Dager S. Psychopharmacologic treatment of panic, generalizedanxiety disorder, and social phobia. Psychiatr Clin North Am. 1993;16:719-735.
15. Westra HA, Stewart SH. Cognitive behavioural therapy and pharmacotherapy: complementary or
contradictory approaches to the treatment of anxiety? Clin Psychol Rev. 1998;18:307-340.
16. Hidalgo RB,Tupler LA, Davidson JR.An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21:864- 872.
17. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial [published corrections appear in JAMA. 2000;284:2450; JAMA. 2001;284:2597]. JAMA. 2000;283:2529-2536.
18. Arch JJ, Craske MG. Implications of naturalistic use of pharmacotherapy in CBT treatment for panic disorder. Behav Res Ther. 2007;45:1435-1447.
19. Basoglu M, Marks IM, Kiliç C, et al.Alprazolam and exposure for panic disorder with agoraphobia: attribution of improvement to medication predicts subsequent relapse. Br J Psychiatry. 1994;164:652-659.
20. Mathew SJ, Coplan JD, Gorman JM. Management of treatment-refractory panic disorder. Psychopharmacol Bull. 2001;35:97-110.
Arch JJ, Craske MG. Implications of naturalistic use of pharmacotherapy in CBT treatment for panic disorder. Behav Res Ther. 2007;45:1435-1447.
Labrecque J, Dugas MJ, Marchand A, Letarte A. Cognitive-behavioral therapy for comorbid generalized anxiety disorder and panic disorder with agoraphobia. Behav Modif. 2006;30:383-410.